Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Is confirmed HIV-uninfected based on negative HIV-1/HIV-2 test result before allocation to study intervention.
Is on stable GAHT and does not intend to change therapy through Week 4 of the study.
Has a low-risk of HIV infection.
Identifies with a gender that is different from that assigned at birth.
You may not be if
Has known current or chronic history of liver disease (e.g, non-alcoholic or alcoholic steatohepatitis) or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome, asymptomatic gallstones, or cholecystectomy), unless the participant has stable liver function tests and no evidence of hepatic synthetic dysfunction.
Has a history of malignancy within 5 years of screening except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or in situ anal cancers.
Has taken cabotegravir, lenacapavir, or any other long-acting HIV prevention product at any time (past or current use).
Is currently participating in or has participated in a clinical study with an investigational compound or device, within 30 days before Day 1 through the duration of the study.
Is expecting to conceive or donate eggs at any time during the study.
